Responses elicited by GPC3-CIRP vaccine not only recognized synthetic 522–530 peptide but could also detect the naturally processed epitope presented by tumor cells, since they were activated by B16F10 tumor cells expressing HLA-A2*01 and GPC3, but not by parental B16F10 cells (Figure 5D). This evidence concerns the gene GPC3 and neoplasm.